Similarly, K-Ras mutations were overrepresented in tumours with lymph-node metastasis (N1 and 2) compared with lymph node-negative (N0) tumours (38.3 vs 25.5%, P=0.03). The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.